Talk:Methyldopa

Medicine Low‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Low	This article has been rated as Low-importance on the project's importance scale.

Pharmacology Stub‑class

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Stub	This article has been given a rating which conflicts with the project-independent quality rating in the banner shell. Please resolve this conflict if possible.
???	This article has not yet received a rating on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Methyldopa.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Methyldopa, in its active metabolite form, leads to increased alfa-2 receptor-mediated inhibition of SNS (centrally and peripherally), allowing PSNS tone to increase. Such activity leads to a decrease in Total Peripheral Resistance (TPR) and Cardiac Output (C.O.).

All drugs in this class can cause rebound hypertension due to an up-regulation of alfa-2 receptors while under the influence of the drug. If the drug is abruptly withdrawan, the "original" as well as "new" receptors become available and cause a severe reaction to the "normal" SNS activity (which is usually in excess). In other words, the SNS typically releases more NE than is needed to activate receptors (leading to a sustained response), and extra receptors leads to an over-response (in this case mediated by alfa-2 receptors leading to vascular smooth muscle CONSTRICTION = rebound hypertension). (That's bad.)

External Links

http://merck-information.com/html/aldomet.html is a legitimate link to one of the manufactures websites, not vandalism or link spam. AA Milne 21:06, 18 October 2006 (UTC)[reply]

As directly stated on merck-information.com:

Please note that http://www.merck-information.com is in no way affiliated with Merck® & Co., inc. or any of its affiliates.

Meaning it is not a legitimate link to one of the manufacturer's websites. Sorry to insist, but spamming (especially sneaky spamming by anons) bugs me. Fvasconcellos 21:17, 18 October 2006 (UTC)[reply]

WikiProject class rating

This article was automatically assessed because at least one WikiProject had rated the article as stub, and the rating on other projects was brought up to Stub class. BetacommandBot 16:30, 10 November 2007 (UTC)[reply]

Corrections and Clean up

The pharmacology section of this article needed some clean up. An important correction was changing the suggestion that methyldopa causes "hypotension" to the statement that it can lower blood pressure. There were unnecessary abbreviations and references to trade names.Verytas (talk) 17:03, 5 October 2009 (UTC)[reply]

Another editor reverted my description of clinical trial. This seems like a routine recording of an uncontroversial fact. It included no medical claims. This doesn't seem to fall under the "secondary source" umbrella. Why revert? Lfstevens (talk) 07:50, 21 February 2018 (UTC)[reply]